Infliximab
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 22 (2) , 107-132
Abstract
Infliximab (Remicade®), a biological disease-modifying antirheumatic drug (DMARD), binds to and inhibits the activity of tumour necrosis factor-α, which is thought to play an important role in the pathophysiology of rheumatoid arthritis. Intravenous infliximab plus methotrexate is recommended in patients with rheumatoid arthritis who have not achieved satisfactory disease control with adequate courses of other DMARDs. Pharmacoeconomic analyses have been based on efficacy data from the pivotal placebo-controlled Anti-Tumour Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) trial in patients with active, refractory rheumatoid arthritis. Infliximab every 8 weeks plus methotrexate demonstrated rapid and sustainable improvements in clinical response, delayed radiographic progression, and/or improved functional status and health-related QOL compared with placebo plus methotrexate at weeks 30, 54 and 102. In cost-utility analyses of infliximab plus methotrexate conducted from a healthcare payer and/or societal perspective in the US, Europe, Portugal, Sweden and the UK, infliximab 3 mg/kg every 8 weeks plus methotrexate was associated with acceptable (<$US50 000 per discounted QALY gained) cost-utility ratios relative to methotrexate alone in patients with active, refractory rheumatoid arthritis. When only direct costs were considered, the lifetime incremental cost per discounted QALY gained with infliximab plus methotrexate relative to methotrexate alone was $US30 500–38 700 (year of costing 1998 or not reported; treatment duration 54 or 102 weeks or lifelong) in the US and Europe analyses, and €39 500 (year of costing not reported; lifelong treatment) in the Portuguese analysis. The cost-utility ratios were more favourable when lost productivity costs or the additional benefit of infliximab on radiographic stabilisation were considered. In the Swedish and UK analyses with a 10-year time horizon, infliximab plus methotrexate for 1 or 2 years was associated with cost-utility ratios of €28 600–56 100 (year of costing not reported) when direct costs were considered, and €3440–48 200 when direct costs plus loss-of-productivity costs were considered. In conclusion, cost-utility analyses, which were based on modelling of data from the pivotal clinical trial of infliximab plus methotrexate, indicate that infliximab plus methotrexate is associated with acceptable cost-effectiveness ratios (<$US50 000 per discounted QALY gained) relative to methotrexate monotherapy in patients with active rheumatoid arthritis who have not responded to previous methotrexate or other DMARD therapy. The cost effectiveness of infliximab versus other DMARDs is at present unclear, but will be clarified when appropriate data from directly comparative clinical and/or pharmacoeconomic studies become available. In patients in whom adequate courses of other DMARDs have failed to achieve satisfactory disease control, infliximab plus methotrexate may prevent or delay disability, which may produce reductions in nondrug costs that can help offset its acquisition cost. Rheumatoid arthritis is a chronic autoimmune disease characterised by symmetrical joint swelling and tenderness, stiffness in the morning that lasts for an hour or longer, subcutaneous rheumatoid nodules, and radiographic evidence of joint damage. An inflammatory cascade, which involves the secretion of inflammatory mediators including tumour necrosis factor-á and results in the destruction and resorption of articular cartilage and bone, appears to play a role in its pathogenesis. Rheumatoid arthritis has a worldwide prevalence of approximately 1%, is generally progressive and is associated with pain, loss of function, disability and an increased risk of premature mortality. Rheumatoid arthritis is associated with substantial direct, indirect and intangible costs, which increase as the severity of the disease increases. Healthcare costs are approximately 2- to 3-fold higher in patients with rheumatoid arthritis than in age-matched individuals without rheumatoid arthritis. Drug costs are the largest contributors to direct healthcare costs; disability-related loss of productivity is the largest contributor to indirect costs. Rheumatoid arthritis can impair the individual’s health-related QOL (HR-QOL), psychological well being and physical function, which results in considerable intangible costs. Recent guidelines recommend early aggressive treatment of rheumatoid arthritis, as early treatment may prevent or delay disease progression. The majority of patients with rheumatoid arthritis should be started on disease-modifying antirheumatic drug (DMARD) therapy within 3 months of diagnosis. Biological DMARDs, such as infliximab, are recommended in the treatment of patients in whom adequate courses of other DMARDs have failed to achieve satisfactory disease control or have resulted in adverse effects limiting their use. In randomised, placebo-controlled, double-blind, multicentre trials, noncomparative trials and in clinical practice, multiple infusions of infliximab in combination with methotrexate resulted in rapid, sustainable clinical responses in patients with active, refractory rheumatoid arthritis who had not responded to previous DMARD therapy. In the pivotal Anti-Tumour Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) trial, response to intravenous infliximab 3 or 10 mg/kg at weeks 0, 2 and 6 plus methotrexate (median dosage 15 mg/week) was rapid (within 2 weeks of starting treatment) and was maintained for up to 102 weeks with continued infliximab treatment every 4 or 8 weeks. American College of Rheumatology (ACR) 20, 50 and 70 response rates were significantly higher with infliximab plus methotrexate than with methotrexate plus placebo after 30 and 54 weeks’ treatment. At 102 weeks, a significantly greater proportion of infliximab...Keywords
This publication has 69 references indexed in Scilit:
- Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2003
- Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart FailureCirculation, 2003
- Methotrexate Intolerance in Elderly Patients with Rheumatoid ArthritisDrugs & Aging, 2003
- Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritisAnnals of the Rheumatic Diseases, 2002
- Living with rheumatoid arthritis: expenditures, health status, and social impact on patientsAnnals of the Rheumatic Diseases, 2002
- A Review of the Direct Costs of Rheumatoid ArthritisPharmacoEconomics, 2001
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- The Underestimated Long Term Medical and Economic Consequences of Rheumatoid ArthritisDrugs, 1995
- TNFα—A PIVOTAL ROLE IN RHEUMATOID ARTHRITIS?Rheumatology, 1992
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980